1. Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population- Based Study 
Øystein Fluge, Bård Mannsåker, Anders Torp, Ingvil Mjaaland, Lars Helgeland, Jan Klos, Olav Mella, Sigbjørn Berentsen, Peter Meyer 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 2, Pages e3 (February 2018)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Outline of Retrospective Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Western Norway 2003 to 2008
Abbreviations: CRu = complete response unconfirmed; CSS = cancer-specific survival; HUS = Haukeland University Hospital; IPI = International Prognostic Index; LDH = lactate dehydrogenase; PD = primary progressive disease; PE = primary extranodal; PET = positron emission tomography; pts = patients; RT = radiotherapy; SUS = Stavanger University Hospital.
Clinical Lymphoma, Myeloma and Leukemia  , e3DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients, With or Without Radiotherapy (RT). The Number of Patients Included (Stages and Response Categories) Are Indicated on Each Panel. Patients With Primary Progressive Disease (PD) and Those Dying During the Chemotherapy Period Were Excluded. (A) Cancer-Specific Survival (CSS) in 211 Patients; (B) CSS in 73 Patients With Complete Response After Chemotherapy; (C) CSS in 138 Patients With Any Residual Mass After Chemotherapy; (D) Overall Survival (OS) in 138 Patients With Any Residual Mass After Chemotherapy; (E) CSS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (F) OS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (G) CSS in 60 Patients With a Clear Residual Mass (PR or CR Unconfirmed [CRu]) After Chemotherapy; (H) OS in 60 Patients With a Clear Residual Mass (PR or CRu) After Chemotherapy
Abbreviation: pts = patients.
Clinical Lymphoma, Myeloma and Leukemia  , e3DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 2
Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients, With or Without Radiotherapy (RT). The Number of Patients Included (Stages and Response Categories) Are Indicated on Each Panel. Patients With Primary Progressive Disease (PD) and Those Dying During the Chemotherapy Period Were Excluded. (A) Cancer-Specific Survival (CSS) in 211 Patients; (B) CSS in 73 Patients With Complete Response After Chemotherapy; (C) CSS in 138 Patients With Any Residual Mass After Chemotherapy; (D) Overall Survival (OS) in 138 Patients With Any Residual Mass After Chemotherapy; (E) CSS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (F) OS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (G) CSS in 60 Patients With a Clear Residual Mass (PR or CR Unconfirmed [CRu]) After Chemotherapy; (H) OS in 60 Patients With a Clear Residual Mass (PR or CRu) After Chemotherapy
Abbreviation: pts = patients.
Clinical Lymphoma, Myeloma and Leukemia  , e3DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions